Tolvaptan can theoretically reduce fluid overload and hydrostatic pressures through its inhibition of antidiuretic hormone. Physicians should particularly emphasize HAlbD treatments as an alternative therapy in patients with severe hypoalbuminemia, as loop diuretics do not restore serum albumin levels as a way to increase oncotic pressure and reduce edema. The gene discussed is ALB; the disease is Hypoalbuminemia.